Steffen Wildum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Steffen Wildum has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Frank Kirchhoff
Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany
11 shared publications - Michael Schindler
Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
8 shared publications - Jan Münch
Institute of Molecular Virology, Ulm University Medical Center, Germany
6 shared publications Klaus Kuhlbusch
F. Hoffmann-La Roche Ltd , Basel
5 shared publications- Aeron C. Hurt
F. Hoffmann‐La Roche Ltd. Basel Switzerland
4 shared publications - Shinya Omoto
Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
4 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Whole Genome Sequencing of Influenza Virus Transmission Pairs Confirms the Efficacy of Baloxavir in Reducing Household Transmission
Background: The CENTERSTONE study demonstrated that treatment of influenza cases with baloxavir significantly reduced the transmission of influenza viruses to household contacts. Because transmission was defined based on the timing of test positivity and subtype match, it is possible that some events reflected co-incident community infection rather than within-household transmission. Such misclassification could affect the significance and magnitude of the baloxavir treatment effect. Methods: Specimens from CENTERSTONE households with ≥2 influenza virus-positive individuals were selected for whole genome sequencing. Consensus sequences and intrahost single nucleotide variants with >2% frequency were determined. Phylogenetic trees of concatenated consensus sequences were constructed by subtype and study site country. Patristic differences between sequences were used to establish thresholds defining household transmission pairs. Results: We obtained complete, high-quality consensus genomes for 376/393 (96%) influenza A specimens and 39/64 (61%) influenza B specimens. Out of the 259 putative transmission pairs analyzed, we had reliable viral sequence data from both individuals in 145. 15/144 (10.4%) pairs had a distance ≥0.0005 (one was indeterminate), 17/145 (11.7%) pairs had a distance ≥0.0003, and 21/145 (14.5%) had a distance ≥0.0002. When excluding pairs based on the most stringent 0.0002 cutoff, the adjusted transmission incidence was 9.2% (95.38% CI, 7.2–11.8) and 12.9% (95.38% CI, 10.2–16.2) (adjusted odds ratio [aOR] 0.69 [95.38% CI, .50–.95]) in baloxavir vs placebo groups, respectively. Conclusions: Application of a stringent, sequence-based cutoff for defining true household pairs supports the outcome of the primary endpoint of CENTERSTONE. Baloxavir treatment of influenza cases can reduce influenza virus transmission in households.
- 13 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessWhole Genome Sequencing of Influenza Virus Transmission Pairs Confirms the Efficacy of Baloxavir in Reducing Household Transmission
Background: The CENTERSTONE study demonstrated that treatment of influenza cases with baloxavir significantly reduced the transmission of influenza viruses to household contacts. Because transmission was defined based on the timing of test positivity and subtype match, it is possible that some events reflected co-incident community infection rather than within-household transmission. Such misclassification could affect the significance and magnitude of the baloxavir treatment effect. Methods: Specimens from CENTERSTONE households with ≥2 influenza virus-positive individuals were selected for whole genome sequencing. Consensus sequences and intrahost single nucleotide variants with >2% frequency were determined. Phylogenetic trees of concatenated consensus sequences were constructed by subtype and study site country. Patristic differences between sequences were used to establish thresholds defining household transmission pairs. Results: We obtained complete, high-quality consensus genomes for 376/393 (96%) influenza A specimens and 39/64 (61%) influenza B specimens. Out of the 259 putative transmission pairs analyzed, we had reliable viral sequence data from both individuals in 145. 15/144 (10.4%) pairs had a distance ≥0.0005 (one was indeterminate), 17/145 (11.7%) pairs had a distance ≥0.0003, and 21/145 (14.5%) had a distance ≥0.0002. When excluding pairs based on the most stringent 0.0002 cutoff, the adjusted transmission incidence was 9.2% (95.38% CI, 7.2–11.8) and 12.9% (95.38% CI, 10.2–16.2) (adjusted odds ratio [aOR] 0.69 [95.38% CI, .50–.95]) in baloxavir vs placebo groups, respectively. Conclusions: Application of a stringent, sequence-based cutoff for defining true household pairs supports the outcome of the primary endpoint of CENTERSTONE. Baloxavir treatment of influenza cases can reduce influenza virus transmission in households.
- Open Access
- 28 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (7) , 645-649
A Phase 3 Safety and Efficacy Study of Baloxavir Marboxil in Children Less Than 1 Year Old With Suspected or Confirmed Influenza
Background: Baloxavir marboxil (baloxavir) inhibits influenza virus cap-dependent endonuclease and has demonstrated safety and efficacy in children 1–<12 years of age. This study assessed the safety and efficacy of baloxavir in children <1 year old. Methods: miniSTONE-1 (NCT03653364) was a Phase III, global, multicenter, single-arm study to evaluate patients <1 year of age who received a single dose of baloxavir (age ≥3 months: 2 mg/kg; <3 months 1 mg/kg). The primary endpoint was safety; secondary endpoints included pharmacokinetics and efficacy (time to alleviation of signs and symptoms, duration of fever and symptoms, antibiotic use and cessation of viral shedding). Results: Overall, 48/49 enrolled patients received baloxavir, of whom 15 had positive centralized influenza reverse transcription polymerase chain reaction tests and comprised the intent-to-treat influenza-infected population. The median age was 6 months and 79.2% of patients were not influenza-vaccinated. Overall, 51 adverse events (AEs) were reported in 23 patients; most were grade 1–2. The most common AEs were diarrhea (16.7%) and vomiting (12.5%). Two patients experienced serious AEs unrelated to treatment. In the intent-to-treat influenza-infected population, median time to alleviation of signs and symptoms was 163.7 hours [95% confidence interval (CI): 122.5–not estimable], median duration of fever was 23.1 hours (95% CI: 22.3–44.6) and median time to cessation of viral shedding was 24.5 hours (95% CI: 24.2–68.6). Conclusions: Baloxavir was well tolerated in children <1 year of age, with no new safety signals identified. Clinical, virological and safety outcomes were consistent with established profiles in adults, adolescents and children 1–<12 years old.
- 28 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (7) , 645-649
Open AccessA Phase 3 Safety and Efficacy Study of Baloxavir Marboxil in Children Less Than 1 Year Old With Suspected or Confirmed Influenza
Background: Baloxavir marboxil (baloxavir) inhibits influenza virus cap-dependent endonuclease and has demonstrated safety and efficacy in children 1–<12 years of age. This study assessed the safety and efficacy of baloxavir in children <1 year old. Methods: miniSTONE-1 (NCT03653364) was a Phase III, global, multicenter, single-arm study to evaluate patients <1 year of age who received a single dose of baloxavir (age ≥3 months: 2 mg/kg; <3 months 1 mg/kg). The primary endpoint was safety; secondary endpoints included pharmacokinetics and efficacy (time to alleviation of signs and symptoms, duration of fever and symptoms, antibiotic use and cessation of viral shedding). Results: Overall, 48/49 enrolled patients received baloxavir, of whom 15 had positive centralized influenza reverse transcription polymerase chain reaction tests and comprised the intent-to-treat influenza-infected population. The median age was 6 months and 79.2% of patients were not influenza-vaccinated. Overall, 51 adverse events (AEs) were reported in 23 patients; most were grade 1–2. The most common AEs were diarrhea (16.7%) and vomiting (12.5%). Two patients experienced serious AEs unrelated to treatment. In the intent-to-treat influenza-infected population, median time to alleviation of signs and symptoms was 163.7 hours [95% confidence interval (CI): 122.5–not estimable], median duration of fever was 23.1 hours (95% CI: 22.3–44.6) and median time to cessation of viral shedding was 24.5 hours (95% CI: 24.2–68.6). Conclusions: Baloxavir was well tolerated in children <1 year of age, with no new safety signals identified. Clinical, virological and safety outcomes were consistent with established profiles in adults, adolescents and children 1–<12 years old.
- Top Cited Papers
- 24 April 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (16) , 1582-1593
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza
Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient evidence that they prevent transmission to contacts. We conducted a multicountry, phase 3b trial to assess the efficacy of single-dose baloxavir treatment to reduce influenza transmission from index patients to household contacts. Influenza-positive index patients 5 to 64 years of age were randomly assigned in a 1:1 ratio to receive baloxavir or placebo within 48 hours after symptom onset. The primary end point was transmission of influenza virus from an index patient to a household contact by day 5. The first secondary end point was transmission of influenza virus by day 5 that resulted in symptoms. Overall, 1457 index patients and 2681 household contacts were enrolled across the 2019-2024 influenza seasons; 726 index patients were assigned to the baloxavir group, and 731 to the placebo group. By day 5, transmission of laboratory-confirmed influenza was significantly lower with baloxavir than with placebo (adjusted incidence, 9.5% vs. 13.4%; adjusted odds ratio, 0.68; 95.38% confidence interval [CI], 0.50 to 0.93; P = 0.01), with an adjusted relative risk reduction of 29% (95.38% CI, 12 to 45). The adjusted incidence of transmission of influenza virus by day 5 that resulted in symptoms was 5.8% with baloxavir and 7.6% with placebo; however, the difference was not significant (adjusted odds ratio, 0.75; 95.38% CI, 0.50 to 1.12; P = 0.16). Emergence of drug-resistant viruses during the follow-up period occurred in 7.2% (95% CI, 4.1 to 11.6) of the index patients in the baloxavir group; no resistant viruses were detected in household contacts. No new safety signals were identified. Treatment with a single oral dose of baloxavir led to a lower incidence of transmission of influenza virus to close contacts than placebo. (Funded by F. Hoffmann-La Roche and others; CENTERSTONE ClinicalTrials.gov number, NCT03969212.).
- 24 April 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (16) , 1582-1593
Top Cited PapersEfficacy of Baloxavir Treatment in Preventing Transmission of Influenza
Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient evidence that they prevent transmission to contacts. We conducted a multicountry, phase 3b trial to assess the efficacy of single-dose baloxavir treatment to reduce influenza transmission from index patients to household contacts. Influenza-positive index patients 5 to 64 years of age were randomly assigned in a 1:1 ratio to receive baloxavir or placebo within 48 hours after symptom onset. The primary end point was transmission of influenza virus from an index patient to a household contact by day 5. The first secondary end point was transmission of influenza virus by day 5 that resulted in symptoms. Overall, 1457 index patients and 2681 household contacts were enrolled across the 2019-2024 influenza seasons; 726 index patients were assigned to the baloxavir group, and 731 to the placebo group. By day 5, transmission of laboratory-confirmed influenza was significantly lower with baloxavir than with placebo (adjusted incidence, 9.5% vs. 13.4%; adjusted odds ratio, 0.68; 95.38% confidence interval [CI], 0.50 to 0.93; P = 0.01), with an adjusted relative risk reduction of 29% (95.38% CI, 12 to 45). The adjusted incidence of transmission of influenza virus by day 5 that resulted in symptoms was 5.8% with baloxavir and 7.6% with placebo; however, the difference was not significant (adjusted odds ratio, 0.75; 95.38% CI, 0.50 to 1.12; P = 0.16). Emergence of drug-resistant viruses during the follow-up period occurred in 7.2% (95% CI, 4.1 to 11.6) of the index patients in the baloxavir group; no resistant viruses were detected in household contacts. No new safety signals were identified. Treatment with a single oral dose of baloxavir led to a lower incidence of transmission of influenza virus to close contacts than placebo. (Funded by F. Hoffmann-La Roche and others; CENTERSTONE ClinicalTrials.gov number, NCT03969212.).
- Open Access
- 21 January 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (1) , e13253
Comparison of influenza viral load in nasopharyngeal and midturbinate swabs
Different specimen types are used for influenza diagnosis but comparative data for viral loads from different swab types are limited. We compared influenza viral loads (determined by quantitative reverse transcription polymerase chain reaction [RT‐PCR]) in 93 paired midturbinate and nasopharyngeal swab aliquots from influenza infected patients enrolled in a phase 3 randomized‐controlled study with the objective of maximizing the number of swabs available for sequence analysis. Midturbinate swabs yielded a 53% lower viral load versus nasopharyngeal swabs, and this difference was similar for influenza A and B. These data suggest that nasopharyngeal swabs might be preferred in diagnostic settings when obtaining higher viral load is important.
- 21 January 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (1) , e13253
Open AccessComparison of influenza viral load in nasopharyngeal and midturbinate swabs
Different specimen types are used for influenza diagnosis but comparative data for viral loads from different swab types are limited. We compared influenza viral loads (determined by quantitative reverse transcription polymerase chain reaction [RT‐PCR]) in 93 paired midturbinate and nasopharyngeal swab aliquots from influenza infected patients enrolled in a phase 3 randomized‐controlled study with the objective of maximizing the number of swabs available for sequence analysis. Midturbinate swabs yielded a 53% lower viral load versus nasopharyngeal swabs, and this difference was similar for influenza A and B. These data suggest that nasopharyngeal swabs might be preferred in diagnostic settings when obtaining higher viral load is important.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (13) , 839-853
Oral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY)
Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults... Tweetable abstract #Bemnifosbuvir is a novel, oral, nonmutagenic, nonteratogenic nucleotide analog with low potential for drug–drug interactions or resistance. Bemnifosbuvir showed a 71% reduction ...
- 1 September 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (13) , 839-853
Open AccessOral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY)
Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults... Tweetable abstract #Bemnifosbuvir is a novel, oral, nonmutagenic, nonteratogenic nucleotide analog with low potential for drug–drug interactions or resistance. Bemnifosbuvir showed a 71% reduction ...
- Open Access
- 29 March 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (6) , 1049-1062
Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19
Observational studies have identified the potential prognostic value for severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) viral load and anti‐SARS‐CoV‐2 antibodies in coronavirus disease 2019 (COVID‐19). However, viral load in nasopharyngeal (NP) swabs produced inconsistent results in prognostic analyses, and the prognostic value of viral load or antibodies has not been confirmed in large clinical trials. COVACTA and REMDACTA were double‐blind, randomized, controlled trials with a combined enrollment of 1078 patients hospitalized with COVID‐19 treated with tocilizumab or placebo in COVACTA or tocilizumab plus remdesivir or placebo plus remdesivir in REMDACTA. We assessed the potential prognostic value of NP and serum SARS‐CoV‐2 viral load and serum anti‐SARS‐CoV‐2 antibodies at baseline as biomarkers for clinical outcomes in patients enrolled in these trials. In adjusted Cox proportional hazard models, serum viral load was a more reliable predictor of clinical outcomes than NP viral load; high serum viral load was associated with higher risk for death and mechanical ventilation/death and lower likelihood of hospital discharge (high vs. negative viral load hazard ratios [95% confidence interval {CI}] were 2.87 [1.57–5.25], 3.86 [2.23–6.68], and 0.23 [0.14–0.36], respectively, in COVACTA and 8.11 [2.95–22.26], 10.29 [4.5–23.55], and 0.21 [0.15–0.29], respectively, in REMDACTA) and high serum viral load correlated with levels of inflammatory cytokines and lung damage biomarkers. High anti‐SARS‐CoV‐2 spike protein antibody (ACOV2S) levels were associated with higher likelihood of hospital discharge (high vs. below the limit of quantification hazard ratios [95% CI] were 2.55 [1.59–4.08] for COVACTA and 1.54 [1.13–2.09] for REMDACTA). These results support the role of baseline SARS‐CoV‐2 serum viral load and ACOV2S antibody titers in predicting clinical outcomes for patients hospitalized with COVID‐19.
- 29 March 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (6) , 1049-1062
Open AccessPrognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19
Observational studies have identified the potential prognostic value for severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) viral load and anti‐SARS‐CoV‐2 antibodies in coronavirus disease 2019 (COVID‐19). However, viral load in nasopharyngeal (NP) swabs produced inconsistent results in prognostic analyses, and the prognostic value of viral load or antibodies has not been confirmed in large clinical trials. COVACTA and REMDACTA were double‐blind, randomized, controlled trials with a combined enrollment of 1078 patients hospitalized with COVID‐19 treated with tocilizumab or placebo in COVACTA or tocilizumab plus remdesivir or placebo plus remdesivir in REMDACTA. We assessed the potential prognostic value of NP and serum SARS‐CoV‐2 viral load and serum anti‐SARS‐CoV‐2 antibodies at baseline as biomarkers for clinical outcomes in patients enrolled in these trials. In adjusted Cox proportional hazard models, serum viral load was a more reliable predictor of clinical outcomes than NP viral load; high serum viral load was associated with higher risk for death and mechanical ventilation/death and lower likelihood of hospital discharge (high vs. negative viral load hazard ratios [95% confidence interval {CI}] were 2.87 [1.57–5.25], 3.86 [2.23–6.68], and 0.23 [0.14–0.36], respectively, in COVACTA and 8.11 [2.95–22.26], 10.29 [4.5–23.55], and 0.21 [0.15–0.29], respectively, in REMDACTA) and high serum viral load correlated with levels of inflammatory cytokines and lung damage biomarkers. High anti‐SARS‐CoV‐2 spike protein antibody (ACOV2S) levels were associated with higher likelihood of hospital discharge (high vs. below the limit of quantification hazard ratios [95% CI] were 2.55 [1.59–4.08] for COVACTA and 1.54 [1.13–2.09] for REMDACTA). These results support the role of baseline SARS‐CoV‐2 serum viral load and ACOV2S antibody titers in predicting clinical outcomes for patients hospitalized with COVID‐19.
- Open Access
- 18 January 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13079
Investigating the transmission of baloxavir‐resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
In a post‐hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI‐184180), we investigated household transmission of baloxavir‐resistant (PA/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA/I38X transmission events was 4.8, assuming wild type and PA/I38X viruses were equally transmissible. However, no PA/I38X viruses were observed. These results suggest a low potential for baloxavir‐resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral/transmission fitness for PA/I38X viruses and/or low viral titres at the time when resistant viruses arise.
- 18 January 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13079
Open AccessInvestigating the transmission of baloxavir‐resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
In a post‐hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI‐184180), we investigated household transmission of baloxavir‐resistant (PA/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA/I38X transmission events was 4.8, assuming wild type and PA/I38X viruses were equally transmissible. However, no PA/I38X viruses were observed. These results suggest a low potential for baloxavir‐resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral/transmission fitness for PA/I38X viruses and/or low viral titres at the time when resistant viruses arise.
- Open Access
- 28 September 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-12
Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model
Influenza antivirals are important tools in our fight against annual influenza epidemics and future influenza pandemics. Combinations of antivirals may reduce the likelihood of drug resistance and improve clinical outcomes. Previously, two hospitalised immunocompromised influenza patients, who received a combination of a neuraminidase inhibitor and baloxavir marboxil, shed influenza viruses resistant to both drugs. Here-in, the replicative fitness of one of these A(H1N1)pdm09 virus isolates with dual resistance mutations (NA-H275Y and PA-I38T) was similar to wild type virus (WT) in vitro, but reduced in the upper respiratory tracts of challenged ferrets. The dual-mutant virus transmitted well between ferrets in an airborne transmission model, but was outcompeted by the WT when the two viruses were co-administered. These results indicate the dual-mutant virus had a moderate loss of viral fitness compared to the WT virus, suggesting that while person-to-person transmission of the dual-resistant virus may be possible, widespread community transmission is unlikely.
- 28 September 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-12
Open AccessAssessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model
Influenza antivirals are important tools in our fight against annual influenza epidemics and future influenza pandemics. Combinations of antivirals may reduce the likelihood of drug resistance and improve clinical outcomes. Previously, two hospitalised immunocompromised influenza patients, who received a combination of a neuraminidase inhibitor and baloxavir marboxil, shed influenza viruses resistant to both drugs. Here-in, the replicative fitness of one of these A(H1N1)pdm09 virus isolates with dual resistance mutations (NA-H275Y and PA-I38T) was similar to wild type virus (WT) in vitro, but reduced in the upper respiratory tracts of challenged ferrets. The dual-mutant virus transmitted well between ferrets in an airborne transmission model, but was outcompeted by the WT when the two viruses were co-administered. These results indicate the dual-mutant virus had a moderate loss of viral fitness compared to the WT virus, suggesting that while person-to-person transmission of the dual-resistant virus may be possible, widespread community transmission is unlikely.
- Open Access
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 884113
Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B
Conventional treatment of chronic hepatitis B (CHB) is rarely curative due to the immunotolerant status of patients. RG7854 is an oral double prodrug of a toll-like receptor 7 (TLR7) agonist that is developed for the treatment of CHB. The therapeutic efficacy, host immune response, and safety of RG7854 were evaluated in the woodchuck model of CHB. Monotreatment with the two highest RG7854 doses and combination treatment with the highest RG7854 dose and entecavir (ETV) suppressed viral replication, led to loss of viral antigens, and induced seroconversion in responder woodchucks. Since viral suppression and high-titer antibodies persisted after treatment ended, this suggested that a sustained antiviral response (SVR) was induced by RG7854 in a subset of animals. The SVR rate, however, was comparable between both treatment regimens, suggesting that the addition of ETV did not enhance the therapeutic efficacy of RG7854 although it augmented the proliferation of blood cells in response to viral antigens and magnitude of antibody titers. The induction of interferon-stimulated genes in blood by RG7854/ETV combination treatment demonstrated on-target activation of TLR7. Together with the virus-specific blood cell proliferation and the transient elevations in liver enzymes and inflammation, this suggested that cytokine-mediated non-cytolytic and T-cell mediated cytolytic mechanisms contributed to the SVR, in addition to the virus-neutralizing effects by antibody-producing plasma cells. Both RG7854 regimens were not associated with treatment-limiting adverse effects but accompanied by dose-dependent, transient neutropenia and thrombocytopenia. The study concluded that finite, oral RG7854 treatment can induce a SVR in woodchucks that is based on the retrieval of antiviral innate and adaptive immune responses. This supports future investigation of the TLR7 agonist as an immunotherapeutic approach for achieving functional cure in patients with CHB.
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 884113
Open AccessToll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B
Conventional treatment of chronic hepatitis B (CHB) is rarely curative due to the immunotolerant status of patients. RG7854 is an oral double prodrug of a toll-like receptor 7 (TLR7) agonist that is developed for the treatment of CHB. The therapeutic efficacy, host immune response, and safety of RG7854 were evaluated in the woodchuck model of CHB. Monotreatment with the two highest RG7854 doses and combination treatment with the highest RG7854 dose and entecavir (ETV) suppressed viral replication, led to loss of viral antigens, and induced seroconversion in responder woodchucks. Since viral suppression and high-titer antibodies persisted after treatment ended, this suggested that a sustained antiviral response (SVR) was induced by RG7854 in a subset of animals. The SVR rate, however, was comparable between both treatment regimens, suggesting that the addition of ETV did not enhance the therapeutic efficacy of RG7854 although it augmented the proliferation of blood cells in response to viral antigens and magnitude of antibody titers. The induction of interferon-stimulated genes in blood by RG7854/ETV combination treatment demonstrated on-target activation of TLR7. Together with the virus-specific blood cell proliferation and the transient elevations in liver enzymes and inflammation, this suggested that cytokine-mediated non-cytolytic and T-cell mediated cytolytic mechanisms contributed to the SVR, in addition to the virus-neutralizing effects by antibody-producing plasma cells. Both RG7854 regimens were not associated with treatment-limiting adverse effects but accompanied by dose-dependent, transient neutropenia and thrombocytopenia. The study concluded that finite, oral RG7854 treatment can induce a SVR in woodchucks that is based on the retrieval of antiviral innate and adaptive immune responses. This supports future investigation of the TLR7 agonist as an immunotherapeutic approach for achieving functional cure in patients with CHB.
- Open Access
- 21 April 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 47, 101409
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
- 21 April 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 47, 101409
Open AccessTocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)